FDA to issue 2 draft guidance documents on lab-developed tests

Article

The U.S. Food and Drug Administration (FDA) recently notified Congress that it intends to issue drafts of guidance documents on lab-developed tests.

Washington, DC-The U.S. Food and Drug Administration (FDA) recently notified Congress that it intends to issue drafts of guidance documents on lab-developed tests.

The draft guidance is titled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs).”

FDA convenes to discuss updating contact lens guidance

The move comes after several senators called for the White House Office of Management and Budget to release the draft guidance for public comment. Earlier this year, the Centers for Disease Control and Prevention (CDC) released a notice that a common lab-developed test for Lyme disease commonly results in false-positives.

“The draft Framework Guidance proposes a risk-based, phased-in framework for oversight of LDTs in a manner that is consistent with FDA’s current regulation of in vitro diagnostic devices,” says Sally Howard, deputy commissioner for policy, planning, and legislation for the FDA, in a letter to the Senate Committee on Health, Education, Labor, and Pensions.

“The accompanying draft guidance describes the manner in which laboratories may provide notification and comply with medical device adverse event reporting,” Howard wrote. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
© 2025 MJH Life Sciences

All rights reserved.